Table of Content

1. Introduction to Tetraspecific Antibodies
1.1 Clinical Overview
1.2 History & Development


2. Tetraspecific Antibodies Mechanism Of Action
2.1 Multispecific Formats
2.2 Tetraspecific Antibodies Bringing Immune Cells & Target Cells Closer


3. Global Tetraspecific Ongoing Clinical Trials By Company, Country, Indication & Phase
3.1 By Company
3.2 By Country
3.3 By Indication
3.4 By Phase


4. Global Tetraspecific Ongoing Clinical Trials Insight
4.1 Research
4.2 Preclinical
4.3 Phase-I
4.4 Phase-II


5. Tetraspecific Antibodies Proprietary Technologies By Company
5.1 Available Proprietary Platforms
5.2 Potential Proprietary Platforms


6. Current Clinical Development & Future Commercialization Outlook
6.1 Current Scenario
6.2 Future Market Commercialization Outlook


7. Tetraspecific Antibodies Therapeutic Approaches
7.1 Tetraspecific Antibodies As Monotherapy
7.2 Tetraspecific Antibodies As Combinational Therapy
7.3 Tetraspecific Antibodies As Targeted Approach

8. Tetraspecific Antibodies Therapeutic Application In Cancer
8.1 Overview
8.2 Ongoing Research & Development


9. Competitive Landscape
9.1 Innate Pharma
9.2 ModeX Therapeutics (OPKO Health)
9.3 Ruijin Hospital
9.4 Sichuan Baili Pharmaceutical
9.5 SystImmune



List of Figures

Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 – Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage

Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells & NK Cells In Close Proximity

Figure 3-1: Global – Tetraspecific Antibodies In Clinical Trials By Company, 2023
Figure 3-2: Global – Tetraspecific Antibodies In Clinical Trials By Country, 2023
Figure 3-3: Global – Tetraspecific Antibodies Clinical Trials By Indication, 2023
Figure 3-4: Global – Tetraspecific Antibodies In Clinical Trials By Phase, 2023

Figure 5-1: ANKET? Platform - Innate Pharma
Figure 5-2: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 5-3: STEALTH – ModeX Therapeutics
Figure 5-4: MSTAR – ModeX Therapeutics
Figure 5-5: Features of MSTAR
Figure 5-6: MATCH – Numab
Figure 5-7: Features of BiXAb
Figure 5-8: Zyngenia Technology Approach
Figure 5-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 5-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 5-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 5-4: IPH6501 - Tetra-Specific NK Cell Engager
Figure 5-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 5-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 5-7: Novel Tetraspecific Format Developed By The Roche Pharma Research & Early Development

Figure 8-1: GNC-038 Phase I/II Study (NCT04606433) – Initiation & Completion Years
Figure 8-2: GNC-038 Phase I/II Study (NCT05192486) – Initiation & Completion Years
Figure 8-3: GNC-038 Phase I/II Study (NCT05485753) – Initiation & Completion Years
Figure 8-4: GNC-038 Phase I/II Study (NCT05623982) – Initiation & Completion Years
Figure 8-5: GNC-038 Phase I/II Study (NCT05627856) – Initiation & Completion Years
Figure 8-6: GNC-039 Phase I/II Study (NCT04794972) – Initiation & Completion Years
Figure 8-7: GNC-035 Phase I Study (NCT05039931) – Initiation & Completion Years